Employees package Qiagen QIAxcel deoxyribonucleic acid (DNA) screening kits at the manufacturing facility of Qiagen NV in Hilden, Germany, on Friday, Aug. 22, 2014. Qiagen investors are betting the busiest year for health-care deals in more than a decade will lure acquirers to one of the industry's most expensive targets. Photographer: Jasper Juinen/Bloomberg via Getty Images
Getty Images

Bloomberg Bloomberg